Has Frances Wallach, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,743 in general payments to Frances Wallach, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Frances Wallach, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Frances Wallach, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Frances Wallach, MD

Infectious Disease · New York, NYNPI 1255360087

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. BD accounts for 91.8% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $1,092 and has fallen 86.9% since, to $143 in 2023.

$1,743in general payments, 2019–2025

Across 5 payments — averaging $348.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

BD$2K
Abbott$143

$244,767in research payments, 2019–2025

Across 5 payments — averaging $48,953 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Gilead$245K

What the payments were for

Consulting fees$1,00057%
Speaking & faculty fees$60034%
Food & beverage$1438%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
BD	4	$1,600
Abbott	1	$143

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CFN MEDMINED$300
CARDIOMEMS$143

How this compares

$1,743 in reported general payments places this provider in the 75th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York →

Medicare billing

Part B allowed, 2024

$163,570

Medicare patients

244

Services billed

1,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	603	$2,393,131
JulucaDolutegravir/Rilpivirine	57	$185,707
DovatoDolutegravir Sodium/Lamivudine	51	$178,430
GenvoyaElviteg/Cob/Emtri/Tenof Alafen	23	$137,610
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf	26	$117,571
CabenuvaCabotegravir/Rilpivirine	19	$113,026
DescovyEmtricitabine/Tenofov Alafenam	39	$82,498
TivicayDolutegravir Sodium	26	$55,578
IsentressRaltegravir Potassium	24	$47,149
OdefseyEmtricitab/Rilpiviri/Tenof Ala	11	$36,159
PrezcobixDarunavir/Cobicistat	11	$24,417
PifeltroDoravirine	13	$22,929
Cefepime Hcl	28	$10,014
Lamivudine HbvLamivudine	27	$4,937
Daptomycin	14	$3,599

Paid to pharmacies, not to this prescriber.

Other infectious disease in New York

Sian JonesNew York$406K
Antonio UrbinaNew York$373K
David BekhorNew York$358K
Genovefa PapanicolaouNew York$209K
Michelle CespedesNew York$125K
Donald KaminskyNew York$120K
Judith AbergNew York$104K
Thomas WalshNew York$98K
Stuart HaberNew York$73K
Michael GaisaNew York$47K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →